302 related articles for article (PubMed ID: 28213817)
1. Breakthrough cancer pain and rational drug use.
Olarte JM
Support Care Cancer; 2017 Apr; 25(Suppl 1):11-17. PubMed ID: 28213817
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription.
Villegas Estévez F; López Alarcón MD; Alonso Babarro A; Olay Gayoso L; de Castro J; Lería-Gelabert M; Melogno-Klinkas M
Curr Med Res Opin; 2020 Aug; 36(8):1383-1391. PubMed ID: 32453602
[No Abstract] [Full Text] [Related]
4. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
5. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
6. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines.
Davies AN; Elsner F; Filbet MJ; Porta-Sales J; Ripamonti C; Santini D; Webber K
BMJ Support Palliat Care; 2018 Sep; 8(3):241-249. PubMed ID: 29875184
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS
BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough Cancer Pain: A Systematic Review of Pharmacologic Management
.
Brant JM; Rodgers BB; Gallagher E; Sundaramurthi T
Clin J Oncol Nurs; 2017 Jun; 21(3 Suppl):71-80. PubMed ID: 28524907
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
12. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
13. What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion.
; Vellucci R; Fanelli G; Pannuti R; Peruselli C; Adamo S; Alongi G; Amato F; Consoletti L; Lamarca L; Liguori S; Lo Presti C; Maione A; Mameli S; Marinangeli F; Marulli S; Minotti V; Miotti D; Montanari L; Moruzzi G; Palermo S; Parolini M; Poli P; Tirelli W; Valle A; Romualdi P
Drugs; 2016 Mar; 76(3):315-30. PubMed ID: 26755179
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough cancer pain: The importance of the right treatment at the right time.
O'Hagan P; Mercadante S
Eur J Pain; 2018 Aug; 22(7):1362-1374. PubMed ID: 29635732
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough Cancer Pain: Ten Commandments.
Mercadante S; Cuomo A
Value Health; 2016; 19(5):531-6. PubMed ID: 27565269
[TBL] [Abstract][Full Text] [Related]
16. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
17. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Husic S; Imamovic S; Matic S; Sukalo A
Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F
Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860
[TBL] [Abstract][Full Text] [Related]
20. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies.
Mercadante S; Valle A; Porzio G; Aielli F; Adile C; Ficorella C; Raineri M; Giarratano A; Casuccio A
Curr Med Res Opin; 2013 Jun; 29(6):667-71. PubMed ID: 23551065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]